文献速递消化系统肿瘤

基于影像引导的预后评分评估免疫检查点抑制剂联合与单药治疗转移性MSI-H结直肠癌患者的获益

Imaging-guided prognostic score-based approach to assess the benefits of combotherapy versus monotherapy with immune checkpoint inhibitors in metastatic MSI-H colorectal cancer patients.
PubMed 文献 · Eur J Cancer · 2024-03-16

这项回顾性研究纳入两个中心150例MSI-H转移性结直肠癌患者,分为训练组105例和验证组45例,基于CT影像量化的肿瘤负荷及临床因素构建风险评分。低评分患者单药与联合免疫治疗生存相似,高评分患者单药治疗生存显著更差。基于总肿瘤体积、病灶数目、腹膜转移和年龄的评分可帮助识别适合单药或联合免疫治疗的患者。

要点

  • 训练组关键变量及权重:总肿瘤体积(截断值73 cm3)1.13、病灶数目(截断值20)0.96、年龄(截断值60)0.91、腹膜转移0.38,风险评分截断值1.36。
  • 训练组高评分患者单药较联合治疗总生存(P=0.004)和无进展生存(P=0.0001)显著更差。
  • 验证组高评分患者单药治疗无进展生存更差(P=0.046),低评分患者单药与联合治疗生存无显著差异。

核心结论

  • 基于总肿瘤体积、病灶数目、腹膜转移和年龄的评分可指导MSI-H转移性结直肠癌治疗决策,帮助肿瘤内科医生识别适合单药或联合免疫检查点抑制剂治疗的患者。

研究设计与样本

  • 回顾性研究,纳入两个中心150例MSI-H转移性结直肠癌患者,分为训练组105例和验证组45例。
  • 放射科医生手动标注胸腹盆CT并计算肿瘤负荷,评估无进展生存,通过递归特征消除筛选变量,使用最大选择秩统计量确定截断值将特征二值化,并以风险比衍生权重构建风险评分。

主要发现

  • 共标注2258个病灶,可重复性极好。
  • 训练组关键变量及权重:总肿瘤体积(截断值73 cm3)1.13、病灶数目(截断值20)0.96、年龄(截断值60)0.91、腹膜转移0.38,风险评分截断值1.36。
  • 训练组低评分患者无论治疗方式总生存和无进展生存相似,高评分患者单药较联合治疗总生存(P=0.004)和无进展生存(P=0.0001)显著更差。
  • 验证组低评分患者单药与联合治疗总生存和无进展生存无显著差异,高评分患者单药治疗无进展生存更差(P=0.046)。

临床怎么用

  • 作者认为,基于总肿瘤体积、病灶数目、腹膜转移和年龄的评分可指导MSI-H转移性结直肠癌治疗决策,帮助肿瘤内科医生识别适合单药和联合免疫检查点抑制剂治疗的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This retrospective study determined survival responses to immune checkpoint inhibitors (ICIs), comparing mono- (mono) and combo-immunotherapy (combo) in patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) by analyzing quantitative imaging data and clinical factors. METHODS: One hundred fifty patients were included from two centers and divided into training (n = 105) and validation (n = 45) cohorts. Radiologists manually annotated chest-abdomen-pelvis computed tomography and calculated tumor burden. Progression-free survival (PFS) was assessed, and variables were selected through Recursive Feature Elimination. Cutoff values were determined using maximally selected rank statistics to binarize features, forming a risk score with hazard ratio-derived weights. RESULTS: In total, 2258 lesions were annotated with excellent reproducibility. Key variables in the training cohort included: total tumor volume (cutoff: 73 cm3), lesion count (cutoff: 20), age (cutoff: 60) and the presence of peritoneal carcinomatosis. Their respective weights were 1.13, 0.96, 0.91, and 0.38, resulting in a risk score cutoff of 1.36. Low-score patients showed similar overall survival and PFS regardless of treatment, while those with a high-score had significantly worse survivals with mono vs combo (P = 0.004 and P = 0.0001). In the validation set, low-score patients exhibited no significant difference in overall survival and PFS with mono or combo. However, patients with a high-score had worse PFS with mono (P = 0.046). CONCLUSIONS: A score based on total tumor volume, lesion count, the presence of peritoneal carcinomatosis, and age can guide MSI-H mCRC treatment decisions, allowing oncologists to identify suitable candidates for mono and combo ICI therapies.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Barbe R, Belkouchi Y, Menu Y, et al. Imaging-guided prognostic score-based approach to assess the benefits of combotherapy versus monotherapy with immune checkpoint inhibitors in metastatic MSI-H colorectal cancer patients. Eur J Cancer. 2024. PMID: 38502988. doi:10.1016/j.ejca.2024.114020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。